Human IgG1 Fc (C103S, M135Y, S137T, T139E, H316K, N317F) Protein, His Tag-Cy5
分子别名（Synonym）
IgG1
表达区间及表达系统（Source）
Human IgG1 Fc Protein, His Tag-Cy5 (IG1-HC2H3) is expressed from human 293 cells (HEK293). It contains AA Glu 99 - Lys 330 (Accession # P01857-1 (C103S, M135Y, S137T, T139E, H316K, N317F)).
Predicted N-terminus: Glu 99
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 28.1 kDa.
偶联（Conjugate）
Cy5
Excitation Wavelength: 651 nm
Emission Wavelength: 670 nm
标记（Labeling）
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with Cy5 using standard chemical labeling method. The residual Cy5 is removed by molecular sieve treatment during purification process.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介绍
Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). IgG1 Fc was reported has a novel role as a potential anti-inflammatory drug for treatment of human autoimmune diseases.
关键字： IgG1 Fc;IgG1 Fc蛋白;IgG1 Fc重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。